Generic semaglutide patents expire globally as Indian pharma prepares cheap weight-loss injections
A key patent expiring yesterday has triggered an immediate surge in generic production, with India poised to unleash low-cost versions of Ozempic and Wegovy that could reshape the global obesity treatment landscape. This development marks a significant shift as pharma stocks jumped 4% following news from China's simultaneous Friday expiry on semaglutide ingredients for both nations' markets ahead of mass rollout plans in March.
Key Points
-
1India plans low-cost generic versions of weight-loss drugs like Ozemip following key patents expiring.
-
2The rollout aims to slash prices for semaglutide injections, making treatments accessible globally rather than just as luxury items.
-
3Pharma stocks surged approximately 4% in anticipation that the patent expiry will reshape global obesity treatment markets.
Developments
Perspectives
India prepares to unleash low-cost generic versions of weight-loss injections like Ozempic after key patents expired, which will dramatically widen access for treatments long considered too expensive.
— [Mar 21] India gears up to produce cheap weight-loss jabs (Taipeitimes)Indian companies are set soon to manufacture low-cost generic versions of drugs such as Ozempic following the expiration of key patents on March 20, a move intended to expand global access.
— [Mar 21] India gears up to produce cheap weight-loss jabs (Taipeitimes)Pharma stocks jumped by approximately four percent after news broke that Ozempic's active ingredient patent had expired in China and the United States, signaling a major shift for global obesity treatment.
— [Mar 20] Weight is over! Pharma stocks jump up to 4% as patent for Ozemipc key ingreident expires; what lies ahead - The Economic TimesThe rollout of generic semaglutide in India could significantly reduce prices and increase access across the developing world.
— [Mar 20] Cheap weight-loss jabs: India set to reshape global obesity fight (Prod-qt-images.s3.amazonaws.com)While cheap Ozempic knockoffs are a game changer for China, they may not be enough on their own; experts warn that these drugs alone cannot solve the complex issue of rising obesity in both countries.
— [Mar 20] Opinion | Why Generic Ozemipc is a game chanerger for Chin and India (Hindustantimes)India has set to launch low-cost generic versions of weight-loss drugs like Ozempic following a key patent expiration, which is expected by year-end across ten countries representing nearly half of global obesity cases. Major pharmaceutical firms in India have already prepared multiple brands for imminent release as clinics report surging demand from patients currently unable to afford the luxury treatments due to high prices.
India is set to produce low-cost generic versions of weight-loss drugs like Ozempic following patent expirations on semaglutide that began with key patents ending on March 20 in India and are projected by the end of 2026. This development aims to expand access for millions, particularly as demand surges globally while current high prices limit affordability among patients who often view these treatments as a luxury item.
Semagludite patents have expired globally as of October 20th. This development has led Indian pharmaceutical company Natco Biopharma (Natcog) launch a generic version at Rs195 per month, which is significantly cheaper than the original drug's price in India and other countries like Canada